ВПЛИВ ДОДАВАННЯ ЕМПАГЛІФЛОЗИНУ ДО СТАНДАРТНОЇ ТЕРАПІЇ НА ЕХОКАРДІОГРАФІЧНІ ПОКАЗНИКИ ТА БІОМАРКЕРИ У ПАЦІЄНТІВ З ІНФАРКТОМ МІОКАРДА ТА ЗНИЖЕНОЮ ФРАКЦІЄЮ ВИКИДУ ЛІВОГО ШЛУНОЧКА
Abstract
The aim of the study was to assess changes in echocardiographic parameters together with biomarkers of myocardial injury, hemodynamic stress, systemic inflammation and fibrosis in patients with reduced left ventricular ejection fraction after myocardial infarction. The investigation was performed at the Feofaniya Clinical Hospital and included patients with left ventricular ejection fraction below 40 % who were assigned either to guideline-based standard therapy or to standard treatment supplemented with empagliflozin. Before and after treatment, left ventricular ejection fraction, global longitudinal strain, indices of diastolic function, left atrial volume index, relative wall thickness and left ventricular myocardial mass index were evaluated, along with serum levels of hsCRP, NT-proBNP, hsTroponin I, GDF-15 and galectin-3, as well as integrated inflammatory indices NLR, PLR, SII, SIRI and AISI. Baseline clinical and anamnestic characteristics were generally comparable between groups, with the exception of a higher rate of uncontrolled hypertension in the empagliflozin group. After treatment, patients who received empagliflozin demonstrated a more pronounced improvement in left ventricular systolic performance and myocardial deformation, with significantly better post-treatment values and greater relative changes in ejection fraction and global longitudinal strain. A more favorable tendency was also observed for diastolic function and structural remodeling parameters. In…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.